Death Receptor 3 (DR3) and its cognate ligand TL1A belong to the tumor necrosis factor superfamily (TNFSF). This sophisticated network of receptor-ligand systems controls innumerable biological processes. For many (if not all) TNFSF ligands and receptors, a role in conditions such as inflammation, tissue development, proliferation, and cell death has been firmly established. However, relatively little is known about DR3 and TL1A. Here, we review novel aspects of DR3 signaling and DR3-associated signaling pathways before summarizing the function of DR3 in the immune system. The emerging role of DR3 in disease will be addressed before we finally critically discuss the potential therapeutic exploitation of this receptor-ligand pair.
The tumor necrosis factor (TNF) superfamily of ligands (TNFSF) and receptors (TNFRSF) orchestrates fundamental biological processes, ranging from inflammation and tissue development to cell death. Death Receptor 3 (DR3) belongs to the so-called 'death receptor' (DR) subgroup of the TNFRSF, which includes prominent and extensively studied members such as TNF receptor 1 (TNFR1), TNFrelated apoptosis-inducing ligand receptor 1 and 2 (TRAILR1/2), and CD95. Until recently, DR3 signaling gained relatively little attention and was suggested to be mechanistically and functionally similar to its close relative TNFR1. However, several exciting studies published during the last years highlighted variegated (patho-)physiological roles for DR3 and its ligand TNF-like protein 1A (TL1A).
In the late 1990s, searches for proteins with sequence similarities to the intracellular parts of TNFR1 and CD95 ultimately led to the discovery of DR3 (also known as Apo-3, TRAMP, WSL-1, LARD, TR3, and TNFRSF25) [1] [2] [3] . DR3 is expressed as type-I transmembrane protein with a length of 417 amino acids and a calculated molecular weight of 47 kDa. Within the TNFRSF, DR3 shows the highest sequence homology to TNFR1. Alternative mRNA splicing generates at least 11 (mostly secreted) isoforms of the protein. The extracellular domain of DR3 includes four cysteine-rich domains (CRD), a structural hallmark of the TNFRSF. Similar to Abbreviations CD, Crohn's disease; CD95, cluster of differentiation 95; cIAP1/2, cellular inhibitor of apoptosis protein 1 and 2; CRD, cysteine-rich domain; DAMP, danger-associated molecular pattern; DD, death domain; DR3, death receptor 3; DSS, dextran sulfate sodium; ERK, extracellular signal-regulated kinase; FOXP3, forkhead box P3; GVHD, graft-versus-host disease; GWAS, genome-wide association studies; HSCT, hematopoietic stem cell transplantation; IBD, inflammatory bowel disease; IFNc, interferon-c; IKK, inhibitor of jB kinase; IL-2, interleukin-2; ILC, innate lymphoid cell; JNK, c-Jun N-terminal kinase; LUBAC, linear ubiquitin assembly complex; MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; MLKL, mixed-lineage kinase domain-like protein; mTORC1, mammalian target of rapamycin complex 1; NEMO, nuclear factor jB essential modulator; RIPK1, receptor-interacting protein kinase 1; SMAC, second mitochondria-derived activator of caspases; TAK1, transforming growth factor beta-activated kinase 1; TCR, T-cell receptor; THD, TNF homology domain; TL1A, TNF-like protein 1A; TNBS, 2,4,6-trinitrobenzene sulfonic acid; TNFR1, tumor necrosis factor receptor 1; TRADD, TNFR-associated death domain; TRAIL-R1/2, TNF-related apoptosis-inducing ligand receptor 1 and 2; UC, ulcerative colitis.
TNFR1, ligand binding is supposed to involve CRD2 and CRD3 [4] . The intracellular part of the receptor harbors the name-giving structural feature of DRs, the so-called death domain (DD). As a protein-protein interaction platform, the DD allows recruitment of adapter proteins and activation of cell death signaling pathways.
In contrast to the ubiquitous expression of its close relative TNFR1, DR3 expression is more restricted and has been reported for innate lymphoid cells (ILCs) [5] [6] [7] , CD4+ [8] [9] [10] [11] [12] and CD8+ T cells [8, 13, 14] , tissueresident memory T cells [15] and B cells [16, 17] . Notably, T-or B-cell receptor activation can upregulate DR3 expression. Hence, DR3 is not only particularly found in lymphoid-rich tissues such as thymus, spleen, and colon [1, 3, 18, 19] , but also in the kidney [20] .
TNF-like protein 1A is the cognate ligand for DR3 and was cloned in 2002 [21] . Activated T cells [22, 23] , macrophages [24] , monocytes [25, 26] , dendritic cells [22, 25, 26] , and endo-/epithelial cells in the kidney [27] were identified as major sources for this ligand. Like most TNFSF ligands, TL1A is a type-II transmembrane protein, but alternative splicing or proteolytic cleavage can generate soluble forms. Both, membranebound and soluble TL1A self-assemble as trimers through homotypic interaction of the TNF homology domain (THD) in the extracellular part of the molecule. Strikingly, membrane-bound and soluble TNF ligands can drastically differ in their ability to activate their cognate receptor(s). In this respect, our lab recently showed that soluble TL1A holds the potential for full-blown DR3 activation [28] , which contrasts many other TNF ligands like TRAIL, OX40L, CD40L, or GITRL [29, 30] . Notably, another TNFRSF member known as Decoy Receptor 3 (DcR3) can compete with DR3 for TL1A binding [21] . The interplay between DcR3/DR3 signaling and the potential pathogenic role of DcR3 has recently been reviewed [31] [32] [33] .
In this review, we will first discuss the molecular mechanism of DR3 signaling and highlight novel aspects before exploring the role of TL1A and DR3 in health and disease. We will review DR3 signaling in immune cells and its functional relevance, but also focus on the emerging role of the TL1A-DR3 axis in chronic inflammatory diseases. Finally, potential therapeutic approaches targeting this receptor-ligand system will be critically assessed.
Molecular mechanisms of DR3 signaling

DR3-associated proinflammatory pathways
Death receptor 3 is capable of inducing at least three completely different signaling pathways (Fig. 1) . The predominant response upon ligand binding is, however, DR3-mediated activation of a proinflammatory, survival-promoting signaling cascade. Mechanistically, TL1A-DR3 interaction triggers recruitment of the adapter protein TNFR-associated death domain (TRADD) via its DD to the cytoplasmic DD of DR3. TRADD seems to be essential for DR3 signaling, as in TRADD-deficient T cells DR3-triggered responses are significantly attenuated [34] . Subsequent recruitment of TNF receptor-associated factor 2 (TRAF2), cellular inhibitor of apoptosis protein 1 and 2 (cIAP1/2), and receptor-interacting protein kinase 1 (RIPK1) occurs within minutes [18, 35] . cIAPs posses E3 ubiquitin ligase activity and conjugate ubiquitin chains to RIPK1, a prerequisite for formation of a first receptor-associated signaling complex (known as complex I). Ubiquitinated RIP1 serves as a docking station for components of the linear-ubiquitin assembly complex (LUBAC), transforming growth factor beta-activated kinase 1 (TAK1) and the IKK complex, consisting of IKKa, IKKb, and NEMO [36] . TAK1 not only phosphorylates the IKK complex and thereby allows NFjB activation but additionally activates mitogen-activated protein kinases (MAPKs) such as p38, c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) [35] .
Cell death pathways triggered by DR3
Although DR3 activation predominantly promotes inflammation and survival, it is certainly not for nothing that this receptor was classified as a 'death receptor' about 20 years ago. Ectopic (over)expression of DR3 in HEK293 cells resulted in membrane blebbing, DNA fragmentation, and loss of viability. Cotransfection of the viral caspase inhibitor CrmA revealed caspase dependency of DR3-mediated cell death, an indicator for apoptosis [1] . Similar findings by several groups firmly established the cytotoxic potential of DR3 [2, 3, 18, 37] , which was also confirmed in endogenously DR3-expressing cell lines such as TF-1 [35] . The latter study provided evidence that TL1A-induced apoptosis only occurred when DR3-mediated activation of the NFjB pathway was blocked, either through pharmacological inhibition or downregulation of cIAP2, an essential component of NFjB-activating complex I [35] . In line with this, subsequent studies demonstrated that cIAP depletion using small molecules mimicking the function of the second mitochondria-derived activator of caspases (SMAC) disrupted complex I formation and NFjB signaling [36] . Our lab extended these findings and showed that in the absence of cIAPs DR3 stimulation allowed full-blown apoptosis induction in the leukemia cell lines TF-1 and Ku812F [28, 38] .
Notably, DR3 expression has also been reported in B cells isolated from patients with chronic lymphocytic leukemia [39] . Combinatorial treatments with SMAC mimetics and DR3 agonists could therefore hold therapeutic potential in some cancer entities. In line with an apoptosis-inducing role in cancer, DR3 is frequently deleted in human neuroblastoma cell lines [40] .
However, caspase-dependent apoptosis is not the only cell death program triggered by DR3. In the absence of cIAPs, the pan-caspase inhibitor zVADfmk unexpectedly failed to rescue cells from TL1A-induced, DR3-mediated cell death. Instead, addition of zVAD-fmk changed the morphology of dying cells from membrane blebbing into swelling and finally bursting. Analyses of the molecular mechanisms underlying this phenomenon revealed that DR3 is capable of activating a caspase-independent, yet regulated cell death program known as necroptosis. cIAP , and TRAF2 to the receptor. RIPK1 undergoes cIAP1/2-mediated ubiquitination with K63-linked polyubiquitin chains that serve as a docking site for TAK1 and the IKK complex (consisting of IKKa, IKKb and NEMO). This receptor-associated signaling complex (designated as 'complex I') is capable to activate the MAPKs JNK, p38, and ERK as well as the NFjB pathway. Recruitment of LUBAC and addition of linear ubiquitin chains to RIPK1 further enhances NFjB activation. At this stage, the primary response of DR3 stimulation is gene activation, which essentially promotes cell survival and inflammation through upregulation of antiapoptotic proteins and cytokines/chemokines, respectively. Cytotoxic DR3 signaling depends on formation of a secondary, cytosolic signaling complex. Complex I, however, actively counteracts the transition to a cytotoxic signaling complex. Therefore, DR3-mediated cytotoxicity occurs only in narrowly defined conditions and depends on blocking complex Imediated upregulation of antiapoptotic genes (such as cFLIP) or disrupted complex I formation/function. (1) Blocking de novo protein synthesis with cycloheximide, for example, abrogates induction of prosurvival NFjB target genes. In this scenario, RIPK1 becomes deubiquitinated, dissociates from the receptor, and interacts with FADD and caspase-8 to form 'complex IIa'. Stepwise caspase-8 activation initiates downstream activation of so-called executioner caspases (e.g., caspase-3 and -7) and finally culminates in caspase-dependent, apoptotic cell death. Caspase-8 also cleaves (and inactivates) RIPK1. (2) Alternatively, when RIPK1 ubiquitination in complex I is blocked by SMAC mimetic-induced degradation of cIAP1/2, a large RIPK1, FADD, and caspase-8 containing complex is formed (referred to as 'complex IIb'). Again, caspase-8 is active and cleaves RIPK1 as well as downstream executioner caspases, altogether leading to apoptosis. Within complex IIb, caspase-8 activity is decisive whether apoptosis or a regulated form of caspase-independent cell death (necroptosis) occurs. (3) Blocking caspase-8 activity in complex IIb leaves RIPK1 intact and allows association with RIPK3. RIPK1 and RIPK3 phosphorylate each other and form an amyloid-like structure called 'necrosome'. Subsequent RIPK3-mediated phosphorylation of MLKL triggers MLKL oligomerization, translocation to the cell membrane and finally membrane rupture, a hallmark of necroptotic cell death.
depletion allowed DR3-triggered formation of a cytosolic 'necrosome' complex [38] , consisting of RIPK1, RIPK3 and the downstream effector molecule mixed-lineage kinase domain-like protein (MLKL). In contrast to apoptotic cell death, necroptosis is thought to have strong inflammatory consequences as released intracellular particles from dying cells act as dangerassociated molecular patterns. Therefore, our observation raises the question whether DR3-induced necroptosis occurs in vivo and whether it is relevant for or contributing to necroptosis-associated diseases. Ischemia-reperfusion injury in the kidney, for example, clearly involves RIPK1-dependent necroptotic cell death and has been shown to be independent of TNFR1 [41, 42] . DR3 is expressed in vascular endothelial cells in the kidney [27] , but the role or relevance of DR3-mediated necroptosis in this organ has to date not been addressed.
DR3 signaling in immune cells
DR3 acts as costimulator on T cells and ILCs
Noteworthy, cytotoxic DR3 signaling was to date mostly observed in transformed and/or immortalized cells (or cell lines). A modest proapoptotic role for DR3 during thymocyte development has been reported [43] , but in primary lymphocytes DR3-triggered cell death is the exception rather than the rule. One physiological role of the TL1A-DR3 system seems to be costimulation of immune effector cells. The effect of DR3 activation varies between T-cell subsets, but overall boosts interleukin-2 (IL-2) signaling. In response to TL1A, activated T cells increase IL-2 production and IL-2 receptor expression [9, 21, 22, 44] . Initially, DR3 was characterized as promotor of Th1 immune responses, because upregulation of interferon-c (IFNc) after TL1A treatment alone or in synergy with IL-12 and IL-18 was observed [15, 21, [45] [46] [47] . However, DR3 function in the immune system is not restricted to Th1 immune responses. TL1A was also reported to promote secretion of IL-4 as well as other Th2-type cytokines and a contribution of TL1A-DR3 to Th2-driven immunopathology was indeed demonstrated [22, 23] . Moreover, DR3 is highly upregulated on Th17 cells and increases their proliferation, but the role of DR3 in Th17 differentiation is controversially discussed [9, 48] . A recent study also elegantly demonstrated involvement of the TL1A-DR3 axis in the differentiation of IL-9 producing T cells [10] . This Tcell population contributes significantly to allergic immune responses, raising the possibility of interfering with DR3 signaling to tackle allergic inflammation.
Recognizing DR3 as a costimulatory molecule on different T-cell subsets brought several groups to think about applying TL1A as vaccine adjuvant in the context of antigen-specific vaccination. As adjuvants, TL1A or DR3-specific agonistic antibodies were able to not only promote CD4+ but also CD8+ T-cell responses [11, 13, 49, 50] . Beside T cells, DR3 modulates the function of ILCs. ILCs emerge from a common lymphoid progenitor, lack B-or T-cell receptors and are grouped into ILC1, ILC2, and ILC3 according to their cytokine release profile. TL1A-DR3 interaction stimulates IL-5 and IL-13 production in ILC2, boosts human ILC2 cytokine release together with IL-25 and IL-33 and enhances IL-22 production of mouse and human ILC3 in synergy with IL-1b and IL-23 [5, 6] . In mouse models of allergic lung disease, DR3 is involved in mounting a proinflammatory ILC2 response and triggers ILC2 expansion [5, 6] . Mice constitutively expressing TL1A, however, display only minor inflammatory changes in the lungs, whereas prominent intestinal inflammation (largely depending on ILC2-derived IL-13) occurs. The latter is accompanied by increased IL-25 and IL-33 levels. Like TL1A, IL-25 and IL-33 are both capable to directly stimulate IL-5 and IL-13 in ILC2. IL-25 and IL-33 are also secreted during parasite invasion and intestinal pathology of TL1A transgenic mice is indeed reminiscent of helminth infection [5] , together pointing to a function for TL1A-DR3 in defense against parasites. Yu et al. [6] reported higher pathogen burden in DR3-deficient mice infected with Nippostrongylus brasiliensis compared to wild-type mice. However, a study by Meylan et al. [5] illustrated unaffected N. brasiliensis clearance in DR3 knockout mice. Thus, the question whether DR3 participates in host defense against parasites remains to be resolved. Beside parasitic infection, a role for TL1A-DR3 in T cell-mediated defense against viruses and bacteria has been reported. Salmonella clearance in DR3-deficient mice was decreased and chemokine release in Staphylococcus epidermidis-triggered peritoneal inflammation was reduced [24, 51, 52] . Moreover, infection with vaccinia virus or murine cytomegalovirus (MCMV) yielded higher virus titers and mortality [8] . In sum, a role for DR3 signaling in T cells and ILCs has been firmly established and future studies will further elucidate DR3 function in infection.
DR3 enhances Treg proliferation
Naturally occurring Tregs (nTregs, here referred to as Tregs) are a subset of T-lymphocytes and molecularly defined by expression of the IL-2 receptor alpha chain CD25, the T cell coreceptor CD4 and the transcription factor forkhead box P3 (FOXP3). The main function of this thymus-derived T-cell population is suppression of immune cells by a variety of mechanisms, thereby ensuring (among others) maintenance of self-tolerance [53] . Tregs can be used therapeutically to control aberrant immune reactions and allo-immune responses like graft-versus-host disease (GVHD). Following allogeneic stem cell transplantation, transferred Tregs successfully prevented GVHD in mice and donor Tregs protected stem cell transplant patients from GVHD in early clinical trials [54, 55] . A major obstacle for Tregbased therapies is their relative paucity, so ex vivo or in vitro expansion is required to reach a therapeutically effective amount of cells. Treg expansion ex vivo is feasible, but maintaining their purity and functionality can be challenging due to overgrowth of effector T cells and loss of suppressive capacity through epigenetic modifications in the foxp3 gene [56] . Alternatively, Tregs can be expanded in vivo by activation of receptors of the TNF superfamily. TNF, for example, triggers Treg proliferation in mice via TNFR2 activation [57, 58] , but systemic TNF administration in humans is likely to cause side effects due to the widespread expression of TNFR1 and/or TNFR2. Notably, murine Tregs are among the rare cell types that constitutively express DR3 [11] . Injection of a DR3-specific agonistic antibody (clone 4C12) or a hexameric TL1A-Ig fusion protein exclusively triggered proliferation of Tregs in mice and increased Treg numbers in vivo three-to fourfold within a few days [11, [59] [60] [61] . This rise in Treg numbers efficiently protected mice from allergic lung inflammation, a model for asthma. Mechanistically, DR3-initiated proliferation was shown to be dependent on T-cell receptor (TCR) stimulation and IL-2, although the details of the involved signaling pathways remain to be elucidated [11] . Another study of the same group demonstrated a role for DR3-mediated Treg expansion in induction and maintenance of transplantation tolerance. A DR3-specific agonistic antibody triggered Treg proliferation and attenuated cardiac allograft rejection in fully major histocompatibility complex (MHC)-mismatched ectopic heart transplants [62] . In line with this, a number of studies recently demonstrated that DR3-mediated proliferation of Tregs attenuated GVHD in mice after allogeneic hematopoietic stem cell transplantation (HSCT) or autologous bone marrow transplantation [60, 61, 63, 64] . Treatment of donor mice with an agonistic anti-DR3 antibody induced Treg proliferation and transfer of DR3-expanded Tregs together with hematopoietic stem cells (HSC) attenuated disease activity in a MHC major mismatch GVHD model [63] . Importantly, the graft-versus-malignancy effect of transplanted donor T cells was preserved. A very recent publication confirmed these findings and elaborated on the phenotype of anti-DR3-treated Tregs in further detail [64] . DR3 stimulation caused a distinct gene expression profile and upregulation of activation markers on Tregs, functionally resulting in enhanced suppressive capacity. In allogeneic HSCT models, concomitant transfer of HSC and donor-derived, DR3-expanded Tregs decreased T-cell infiltration into GVHD target tissues, lowered serum levels of proinflammatory cytokines (such as TNF or IFNc), reduced GVHD disease activity and prolonged survival [64] . In the HSCT setting, expanding Tregs of the recipient via anti-DR3 treatment also attenuated GVHD [64] . Intriguingly, in mice with already established active GVHD, DR3 expression in Tregs was diminished but increased in conventional CD4+ and CD8+ T cells. After the onset of acute, HSCT-induced GVHD, treating mice with anti-DR3 antibody enhanced proliferation of conventional donor T cells (but not donor or recipient Tregs), aggravated allo-immune responses and accelerated death. Therefore, whether DR3 fuels or dampens inflammation critically depends on the timing of DR3 activation. Of note, Tregs not only express DR3 but also TL1A. In a murine colitis model, expression levels of TL1A inversely correlated with the suppressive capacity of Tregs [65] .
Beside thymus-derived, naturally occurring Tregs, a second DR3-expressing Treg population emerges from conventional T cells that upregulate FOXP3 after encountering foreign antigens in the periphery and is therefore classified as induced regulatory T cells (iTregs). TL1A inhibits the differentiation of iTregs in vitro [59, 66] . In mucosal tissues, iTregs are critically involved in maintaining tolerance to endogenous and environmental (self-) antigens. DR3 activation might therefore not only exacerbate inflammation-driven diseases through costimulation of (activated) DR3-positive effector T cells but also via inhibition of iTreg differentiation.
Collectively, these studies highlighted a relevant role for the TL1A-DR3 signaling axis in murine Tregs. For human Tregs, however, neither expression nor a potential function of DR3 have until recently been investigated. Our lab proved DR3 expression on isolated human Tregs and showed TL1A-induced activation of MAPKs and the NFjB pathway [12] . Furthermore, addition of TL1A during in vitro expansion increased the yield of human Treg while their suppressive capacity was retained. Intriguingly, human Tregs ex vivo and murine Tregs in vivo share certain features: DR3-mediated proliferation is dependent on both, IL-2 and TCR signaling [11] . Dependence on TCR signals provides a possible explanation for the selective DR3-mediated Treg proliferation in vivo. Tregs recognize self-antigens via their TCR. The continuous availability of self-antigens causes tonic TCR stimulation in Tregs (but not other T-cell subsets) and readiness to proliferate upon DR3 activation. The dependency of DR3-triggered T-cell proliferation on TCR activation became apparent in studies that used DR3 agonists as vaccination adjuvants: effector T-cell proliferation was only triggered when DR3 agonists were administered together with foreign antigens [67] . Intriguingly, murine Tregs in vivo and human Tregs ex vivo proliferated in the presence of rapamycin [11, 12] , an inhibitor of mammalian target of rapamycin complex 1 (mTORC1). Clinically, rapamycin is an immunosuppressive used to prevent rejection of transplants. In this context, combining rapamycin with DR3 agonists could further diminish allo-reactive immune responses.
Targeting of TNFRSF members on Tregs may not be restricted to increase proliferation and suppressive capacity of this cell population. Blockade of TNFRSF activation can also withdraw Tregs from vitally important signals for function and survival. For example, Treg-imposed restrictions of immune reactions critically limit effectiveness of cancer immunotherapy. A recent study showed that blocking TNFR2, a marker of highly suppressive Tregs, inhibited Treg proliferation in the tumor environment while effector T cells were not affected [68] . To date, it is not known whether inhibition of DR3 signaling in humans affects the regulatory function of Tregs. Answering this question could also clarify whether DR3 signaling has a unique role in human Tregs or whether its loss can be compensated through other Treg-associated TNFRSF members such as 4-1BB, GITR, OX40, and CD30.
DR3 in chronic inflammatory disease
As noted above, DR3 expression is not only restricted to Tregs but also found on activated effector T cells. Consistent with being a T-cell costimulator, a role for DR3 and its ligand TL1A has been found in not only a variety of T-cell-dependent but intriguingly also T-cellindependent autoimmune diseases. Studies with TL1A-and DR3-deficient mice demonstrated a critical involvement for this receptor-ligand system in induction and maintenance of chronic inflammation. Generally, TL1A-induced expansion of activated effector T-cells in inflamed tissues and organs apparently worsens chronic inflammatory diseases, whereas loss of TL1A or DR3 reduces disease severity. The role of TL1A and DR3 will be discussed in more detail below.
The role of TL1A/DR3 in inflammatory bowel disease
In mouse models, constitutive TL1A expression triggered intestinal inflammation [5] , whereas loss of TL1A or DR3 attenuated disease severity in chronic dextran sulfate sodium (DSS) colitis and acute 2,4,6-trinitrobenzene sulfonic acid (TBNS) colitis [69, 70] . In acute DSS colitis, TL1A and DR3 surprisingly have a protective role through the expansion of regulatory T cells [51] . In humans, TL1A is upregulated in the inflamed intestine of patients suffering from ulcerative colitis (UC) or Crohn's Disease (CD) and TL1A levels in the serum are elevated [47, [71] [72] [73] [74] [75] . Plasma cells in the lamina propria are the major source for TL1A in UC, whereas in CD T cells and macrophages are responsible for TL1A secretion [71, 76] . TL1A serum levels are increased in patients with active and inactive UC. In CD, only active disease is associated with elevated systemic TL1A concentrations. Anti-TNF treatment diminishes intestinal TL1A expression in CD patients, which is in agreement with a recent study that reported regulation of TL1A expression in CD through mucosa-derived factors including TNF [47, 77] . Associations between TL1A gene polymorphism and development of CD in European, Korean, Japanese, and Chinese populations have been assessed by several Genome Wide Association Studies (GWAS) and in sum strengthen the role of TL1A as driver of inflammatory bowel diseases (IBD) [78] [79] [80] [81] [82] [83] [84] . Remarkably, the link between TL1A gene polymorphisms and CD was confirmed in different ethnical groups and in patients of almost all ages, which distinguishes TL1A from a variety of other genes associated with CD. The GWAS findings regarding UC are somewhat contradicting: some studies found an association with TL1A gene variants, whereas others did not [83, 85] . Additionally, involvement of TL1A in the pathogenesis of irritable bowel syndrome seems possible as a study demonstrated associations with TL1A polymorphisms and altered mucosal TL1A expression [86] . Beside TL1A, DR3 expression on T cells in the lamina propria of UC and CD patients is concomitantly increased and was also reported on peripheral blood mononuclear cells of patients with inflammatory bowel disease [71, 75] . The frequency of DR3-positive cells positively correlated with levels of other markers of inflammation such as C-reactive protein [87] .
DR3 signaling in arthritis and psoriasis
A role for DR3 in arthritis was inferred from mouse models of collagen-and antigen-induced arthritis. Loss of DR3 or TL1A or administration of TL1A antagonists in these models reduced joint damage, lowered serum anti-collagen antibody titers as well as clinical disease scores [17, 88, 89] . In contrast, treatment with recombinant TL1A aggravated collagen-induced arthritis in mice and boosted anti-collagen antibody levels [17, 90] . Mechanistically, TL1A-DR3 signaling provokes joint damage by enhancing osteoclast differentiation and their resorptive activity [88, 91] . Obviously, these findings in mouse models of arthritis highlight a contributing role for TL1A-DR3 to disease pathology and raise the question whether this is also true in humans. Indeed, TL1A levels are high in serum and synovial fluid of patients suffering from rheumatoid arthritis (RA), especially in cases of serve and/or late-stage disease [90, 92] . Notably, TL1A serum levels in RA patients correlate with disease activity and presence of rheumatoid factor, a RA-specific autoantibody [93] . In rheumatoid factor-positive patients, higher TL1A levels are presumably attributable to two sources: firstly, to monocytes which secrete the cytokine in response to stimulation with circulating immune complexes; and secondly, to chondrocytes and synovial fibroblasts, both of which are able to secrete TL1A upon stimulation with TNF or IL-1b [90] . Notably, serum TL1A decreases after TNF-blockade [93] . Additionally, a role for TL1A in atherosclerosis related to chronic inflammation is discussed. Serum levels of TL1A correlate with development of carotid plaques in follow-up RA patients and DR3-dependent changes in the aorta during inflammatory arthritis in mice have been described [94, 95] . However, despite TL1A upregulation in RA patients, until now GWAS could not link TL1A gene polymorphisms to a risk for RA development.
Another immune-mediated disease in humans that exhibits TL1A-DR3 contribution is psoriasis and psoriasis arthritis. Several genetic risk variants are associated with this multifactorial skin pathology [96] . Elevated TL1A levels are detectable in serum of psoriasis patients and decline upon psoriasis treatment [97] . DR3 and TL1A expression is found in skin lesions, but not in healthy skin areas of patients with active psoriasis, indicating a pathogenic role. Immunohistochemistry and gene expression analysis of psoriatic skin lesions suggest TL1A expression by numerous immune and nonimmune cells, for example, keratinocytes, endothelial cells, neutrophils, lymphocytes, and monocytes [98, 99] .
TL1A/DR3 in other inflammation-driven diseases
The TL1A-DR3 involvement has been investigated in several other inflammatory diseases. Enhanced TL1A expression was detected in serum and liver tissue of patients with early-and late-stage primary biliary cholangitis and declined upon treatment [100] . Liver biopsies demonstrated TL1A expression in blood vessels, endothelial cells, Kupffer cells, and infiltrating monocytes. Besides, a GWAS performed in a Japanese cohort identified TL1A as a susceptibility locus of primary biliary cholangitis. However, this association could not be confirmed in an European population [101] . A correlation between elevated TL1A levels in serum and disease activity was also noted for patients with ankylosing spondylitis [102] . Again, anti-TNF therapy lowered TL1A levels. Mouse models also suggest an involvement of TL1A and DR3 in the pathogenesis of autoimmune encephalitis and experimental autoimmune uveo-retinitis [9, 22, 103] .
In sum, the aforementioned studies analyzing genome-wide association, patient samples, and animal models provide several lines of evidence that emphasize a critical contribution of DR3 and its ligand TL1A to multiple inflammatory diseases. Therapeutically, interfering with the TL1A-DR3 pathway could be a promising approach. Compared to other TNFRSF, expression of DR3 is restricted to relatively few cell types in vivo. Targeting the DR3 pathway might therefore have fewer immune-compromising side effects than, for example, targeting TNF signaling (as TNFR1 is expressed almost ubiquitously on nucleated cells). Intriguingly, we demonstrated that TL1A stimulation in combination with SMAC mimetics switches DR3 response from proinflammatory signaling toward cell death [28] . Eventually, this could be exploited to eliminate DR3-expressing cells that contribute to progression of diseases at inflammation sites.
Conclusions and perspectives
Since the discovery of DR3, substantial progress has been made to clarify fundamental molecular mechanisms of DR3 signal transduction and DR3 participation in a variety of pathologies. DR3 is also capable to trigger apoptotic and necroptotic cell death, although this requires narrowly defined conditions. Whether cytotoxic DR3 signals in vivo contribute to or are involved in disease development remains to be elucidated. Physiologically, DR3 predominantly activates proinflammatory and prosurvival pathways, which is essentially consistent with its role as a costimulatory molecule. Multiple mouse models revealed a contributory role for DR3 and its ligand TL1A in different inflammation-driven pathologies and GWAS suggested relevance of TL1A and DR3 in a variety of human diseases. These findings indicate that blockade of DR3 signaling in context of chronic inflammatory diseases may provide beneficial anti-inflammatory effects, similar to widely utilized anti-TNF compounds. Indeed, first attempts have already been made to generate high-affinity TL1A-blocking molecules for this purpose [104] . Interest in DR3 was somewhat sparked when elegant mouse studies consistently reported the potential of DR3 to selectively expand Tregs in vivo. Our lab strengthened the role of DR3 in human Tregs, which could potentially be exploited to prevent overwhelming autoreactive immune responses in patients. However, it should be kept in mind that DR3 expression is not only an exclusive feature of Tregs, but can also be found on activated conventional T cells. DR3 activation in an already established inflammation might boost the response of conventional T cells rather than attenuating the inflammatory response through expansion of Tregs. Thus, the inflammatory status quo of tissues, organs, or the entire host organism could be critically involved in predicting the cellular response to DR3 activation. Especially for future therapeutic exploitation of the TL1A-DR3 axis, this has important implications and should be carefully assessed.
